WHAT IS CLAIMED IS:

1. A purified bacteriophage having a genome which comprises at least 99% sequence identity to the nucleotide~~comprising the nucleic acid~~ sequence of SEQ ID NO:2, and has antibacterial activity against *Enterococcus faecalis* or *Enterococcus faecium*.

2. A pharmaceutical composition comprising the bacteriophage of claim 1 and a pharmaceutically acceptable carrier.

3. The pharmaceutical composition of claim 2, further comprising one or more additional bacteriophages effective against *Enterococcus faecalis* or *Enterococcus faecium*.

4. The pharmaceutical composition of claim 2, further comprising one or more additional bacteriophages effective against bacteria other than *Enterococcus faecalis* or *Enterococcus faecium*.

5. An isolated lysin protein from bacteriophage F170/08, having the amino acid sequence of SEQ ID NO:184 or SEQ ID NO:203, or a fragment thereof having antibacterial or antimicrobial activity against *Enterococcus faecalis* or *Enterococcus faecium*, wherein said bacteriophage F170/08 comprises the nucleic acid sequence of SEQ ID NO:2.

6. The fragment of claim 5, wherein said fragment is a CHAP domain isolated from a polypeptide having the amino acid sequence of SEQ ID NO:184 or SEQ ID NO:203.

7. An isolated tail tape measure protein or tail protein from bacteriophage F170/08, having the amino acid sequence of SEQ ID NO:204 or a fragment thereof having antibacterial or antimicrobial activity against *Enterococcus faecalis* or *Enterococcus faecium*, wherein said bacteriophage F170/08 comprises the nucleic acid sequence of SEQ ID NO:2.

8. A pharmaceutical composition comprising the isolated protein or fragment of any one of claims 5-7 and a pharmaceutically acceptable carrier.

9. The pharmaceutical composition of claim 8, comprising the isolated protein having the amino acid sequence of SEQ ID NO:184, SEQ ID NO:203 or SEQ ID NO:204, or a fragment thereof, having antibacterial or antimicrobial activity against *Enterococcus faecalis* or *Enterococcus faecium*.

10. The pharmaceutical composition of claim 9, further comprising one or more bacteriophages or additional proteins effective against *Enterococcus faecalis* or *Enterococcus faecium* and/or effective against bacteria other than *Enterococcus faecalis* or *Enterococcus faecium*.

11. An isolated nucleic acid comprising a nucleotide sequence encoding the protein or fragment of any one of claims 5-7.

12. Use of a therapeutically effective amount of the pharmaceutical composition of any one of claims 2-4 or 8-10 in the manufacture of a medicament for treating or reducing the incidence of a bacterial infection by *Enterococcus faecalis* or *Enterococcus faecium* in a subject in need thereof.

~~13. The use of claim 12 wherein said bacterial infection is an infection by *Enterococcus faecalis* or *Enterococcus faecium*.~~

~~14~~13. The use of claim 12, wherein the infection is a nosocomial infection.

~~15~~14. The use of claim 12, wherein the composition is administered topically.

~~16~~15. The use of claim 12, wherein the subject is a mammal.

~~17~~16. The use of claim ~~16~~15, wherein the mammal is a human.

~~18~~17. The use of claim 12, wherein the infection treated is an infection of the skin.

~~19~~18. The use of claim ~~18~~17, wherein said infection of the skin is an infection associated with an ulcer or a skin structure infection.

~~20~~19. The use of claim ~~18~~17, wherein said infection of the skin is an infection associated with a diabetic foot ulcer.

~~21~~20. A method for diagnosing *Enterococcus faecalis* or *Enterococcus faecium* as the causative agent of a bacterial infection comprising:

(i) culturing a tissue sample from a patient;

(ii) contacting the culture of step (i) with the bacteriophage of claim 1, or the protein or fragment of any one of claims 5-7; and

(iii) monitoring for evidence of growth or lysis of the culture;

wherein evidence of lysis of the culture indicates that the culture comprises *Enterococcus faecalis* or *Enterococcus faecium*.

~~22~~21. The method of claim ~~21~~20, wherein the tissue sample is a sample of blood, fluid, tissue biopsy or swab collected from said patient.

~~23~~22. A method for reducing or inhibiting colonization or growth of *Enterococcus faecalis* or *Enterococcus faecium* bacteria on a solid surface comprising contacting said solid surface with the bacteriophage of claim 1, or the protein or fragment of any one of claims 5-7.

~~24~~23. The method of claim ~~23~~25, wherein said solid surface is the surface of a hospital apparatus or a piece of hospital equipment.

~~25~~24. The method of claim ~~24~~23, wherein said apparatus of equipment is a surgical apparatus or a piece of surgical equipment.

~~26~~25. Use of the bacteriophage of claim 1, or the protein or fragment of any one of claims 5-7, in the manufacture of a medicament for reducing or inhibiting an infection associated

with colonization or growth of *Enterococcus faecalis* or *Enterococcus faecium* on a biological surface of a mammal that is contacted therewith.

~~27~~26. The use of claim ~~26~~25, wherein said surface is the skin or a mucus membrane of a mammal.

~~28~~27. The use of claim ~~27~~26, wherein said mammal is a human.

~~29~~28. The use of claim 12, wherein said medicament further comprises

(i) an antibiotic for treating infection by *Enterococcus faecalis* or *Enterococcus faecium*;

(ii) one or more additional bacteriophage known to have antibacterial or antimicrobial activity against *Enterococcus faecalis* or *Enterococcus faecium*; and/or

(iii) one or more additional bacteriophage known to have antibacterial or antimicrobial activity against bacteria other than *Enterococcus faecalis* or *Enterococcus faecium*.